To PRLNer's,
I thought I would break out of our current rut by responding to myself.
This morning I took the plunge and doubled by PRLN investment. I was closely following several other attractive stocks and choose Paracelsian. It is kind of funny when you can account for a significant fraction of the trading activity!
I have based my purchase on several factors. Not because I am a "true blue" investor like Richard D. Admittedly, I am considering this as a possible short-term play. I intend to keep my original investment. Here are my thoughts...
(1) There is little downside at this time. By chart alone, I see that things are stabilized. It would not be a bad idea at this time to accumulate below $2. There is great potential upside in...
(a) the very short term, i.e., next week at the SB conference
(b) short-term, over the next 2 months AndcroVir and possibly
AndroCAr will hit the markets. This may even make the news.
If it stirs up controversy over "dietary supplement", and I
think it will, Paracelsian will get much-needed exposure.
(c) mid-term, say 6 months, the AndroCar study results will come
in and we will see how the sales of products are going
I also expect to see some scientific recognition, e.g., a
paper or conference presentation which will be helpful.
(d) long-term, 1 year or more, I personally hope to see more
clinical testing of their products, perhaps even the East-West
candidates.
(2) Tax implications. Several months back I increased my position
at $2 3/4. If I am wrong and nothing happens to PRLN for the next month or so, I can sell at the current level for a tax loss and I will still be in for my original level, only at a lower basis. I would suggest for anyone in a similar position to consider buying some PRLN now, since you need to wait a month to take a loss. (I know what people are thinking:its way to early to thing about tax-loss selling!)
This again "limits the downside" in a way.
I'm sure there's much more I'm forgetting right now, but suffice it to say despite the lackluster performance lately, I still like PRLN very much. Another reason is that PRLN usually does well about this time of year. Last year in February, I was quite surprised to see PRLN double in just about a day on some in vitro news about AndoCar inhibiting cancer growth.
In the words of...actually who started this first?...anyway...
GO PRLN!
Rick |
